Monthly Update Anti-infectives: LY333328, a new glycopeptide active against vancomycin-resistant enterococci

Abstract

LY333328 is a novel glycopeptide from Lilly Research Laboratories which is claimed to have activity both in vitro and in vivo against vancomycin-resistant enterococci. Information on this compound has been published at three recent meetings, the 7th European Congress of Clinical Microbiology and Infectious Diseases (March 26 - 30, Vienna, Austria); On the Frontier of Antibacterial Drug Discovery (April 27 - 28, Princeton, USA); and the 19th International Chemotherapy Congress (July 16 - 21, Montreal, Canada). This update draws together the published data and attempts to assess the potential therapeutic use of this interesting new compound.